Abstract
Apolipoprotein D (apoD) is an atypical plasma apolipoprotein and, based on its primary structure, it is a member of the lipocalin protein superfamily. Lipocalins have been extensively used as disease markers and, accordingly, apoD has become increasingly recognized as an important factor in the pathology of human neurodegenerative and neuropsychiatric disorders. ApoD expression is increased in the plasma and brains of subjects with schizophrenia and bipolar disorder, suggesting that it acts as a marker for disease pathology. ApoD also exhibits complex regulation by antipsychotic drug treatment and may represent a distinguishing mechanism of typical versus atypical drugs. The precise role of apoD in the CNS and disease remains to be elucidated, but recent findings have suggested that it plays an important role in the regulation of arachidonic acid signaling and metabolism providing further support for phospholipid membrane pathology in schizophrenia.
Keywords: pharmacotherapy, pathophysiology, apolipoprotein d, psychiatric disorders, lipocalin protein superfamily
Current Molecular Medicine
Title: From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders
Volume: 3 Issue: 5
Author(s): E. A. Thomas, D. L. Copolov and J. G. Sutcliffe
Affiliation:
Keywords: pharmacotherapy, pathophysiology, apolipoprotein d, psychiatric disorders, lipocalin protein superfamily
Abstract: Apolipoprotein D (apoD) is an atypical plasma apolipoprotein and, based on its primary structure, it is a member of the lipocalin protein superfamily. Lipocalins have been extensively used as disease markers and, accordingly, apoD has become increasingly recognized as an important factor in the pathology of human neurodegenerative and neuropsychiatric disorders. ApoD expression is increased in the plasma and brains of subjects with schizophrenia and bipolar disorder, suggesting that it acts as a marker for disease pathology. ApoD also exhibits complex regulation by antipsychotic drug treatment and may represent a distinguishing mechanism of typical versus atypical drugs. The precise role of apoD in the CNS and disease remains to be elucidated, but recent findings have suggested that it plays an important role in the regulation of arachidonic acid signaling and metabolism providing further support for phospholipid membrane pathology in schizophrenia.
Export Options
About this article
Cite this article as:
Thomas A. E., Copolov L. D. and Sutcliffe G. J., From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders, Current Molecular Medicine 2003; 3 (5) . https://dx.doi.org/10.2174/1566524033479681
DOI https://dx.doi.org/10.2174/1566524033479681 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Post-Transcriptional Regulation of HSP70 Expression Following Oxidative Stress in SH-SY5Y Cells: The Potential Involvement of the RNA-Binding Protein HuR
Current Pharmaceutical Design 2,5-Diketopiperazines as Neuroprotective Agents
Mini-Reviews in Medicinal Chemistry Chemistry and Biology of Thyrotropin-Releasing Hormone (TRH) and its Analogs
Current Medicinal Chemistry Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
CNS & Neurological Disorders - Drug Targets Noncoding RNAs and Intracerebral Hemorrhage
CNS & Neurological Disorders - Drug Targets A New Model for Academics Based Drug Discovery
Current Alzheimer Research The Protective Effect of Jatrorrhizine Against Oxidative Stress in Primary Rat Cortical Neurons
CNS & Neurological Disorders - Drug Targets Cellular Functions of RNA-Binding Motif Protein 3 (RBM3): Clues in Hypothermia, Cancer Biology and Apoptosis
Protein & Peptide Letters Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer
Current Medicinal Chemistry Stem Cell Lineage Commitment by Electrical Fields and the Potential Application in Drug Discovery
Current Drug Metabolism Fatty Acid Amide Hydrolase Inhibitors – Progress and Potential
CNS & Neurological Disorders - Drug Targets Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases
Current Drug Metabolism Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Current Overview of Inorganic Nanoparticles for the Treatment of Central Nervous System (CNS) Diseases
Current Nanomaterials Outcomes of Perilla Seed Oil as an Additional Neuroprotective Therapy in Patients with Mild to Moderate Dementia: A Randomized Control Trial
Current Alzheimer Research Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool
Current Protein & Peptide Science Proteomics as Applied to Inherited Metabolic Diseases
Current Proteomics Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry Neuroprotection by vitamin C against ethanol -induced neuroinflammation associated neurodegeneration in developing rat brain
CNS & Neurological Disorders - Drug Targets